Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
43 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Hemorrhage - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Hemorrhage - Pipeline Review, H2 2014', provides an overview of the Hemorrhage's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Hemorrhage, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemorrhage and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Hemorrhage - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Hemorrhage and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Hemorrhage products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Hemorrhage pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hemorrhage - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hemorrhage pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Hemorrhage Overview 6 Therapeutics Development 7 Pipeline Products for Hemorrhage - Overview 7 Pipeline Products for Hemorrhage - Comparative Analysis 8 Hemorrhage - Therapeutics under Development by Companies 9 Hemorrhage - Therapeutics under Investigation by Universities/Institutes 10 Hemorrhage - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Hemorrhage - Products under Development by Companies 13 Hemorrhage - Products under Investigation by Universities/Institutes 14 Hemorrhage - Companies Involved in Therapeutics Development 15 Cellphire, Inc. 15 Digna Biotech, S.L. 16 Grifols, S.A. 17 Haemostatix Ltd 18 QRxPharma Limited 19 Serendex Pharmaceuticals A/S 20 Thrombotargets Corporation 21 Hemorrhage - Therapeutics Assessment 22 Assessment by Monotherapy Products 22 Assessment by Target 23 Assessment by Mechanism of Action 25 Assessment by Route of Administration 27 Assessment by Molecule Type 29 Drug Profiles 31 DB-055 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 eptacog alfa - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 fibrinogen concentrate (human) - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 PeproStat - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Protein for Hematological Disorders, Dermatology, Shock and Injury - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Q-8008 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Thrombosomes - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 TT-111 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 TT-112 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 V-0801 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Hemorrhage - Dormant Projects 41 Appendix 42 Methodology 42 Coverage 42 Secondary Research 42 Primary Research 42 Expert Panel Validation 42 Contact Us 43 Disclaimer 43
List of Tables Number of Products under Development for Hemorrhage, H2 2014 7 Number of Products under Development for Hemorrhage - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Number of Products under Investigation by Universities/Institutes, H2 2014 10 Comparative Analysis by Clinical Stage Development, H2 2014 11 Comparative Analysis by Early Stage Development, H2 2014 12 Products under Development by Companies, H2 2014 13 Products under Investigation by Universities/Institutes, H2 2014 14 Hemorrhage - Pipeline by Cellphire, Inc., H2 2014 15 Hemorrhage - Pipeline by Digna Biotech, S.L., H2 2014 16 Hemorrhage - Pipeline by Grifols, S.A., H2 2014 17 Hemorrhage - Pipeline by Haemostatix Ltd, H2 2014 18 Hemorrhage - Pipeline by QRxPharma Limited, H2 2014 19 Hemorrhage - Pipeline by Serendex Pharmaceuticals A/S, H2 2014 20 Hemorrhage - Pipeline by Thrombotargets Corporation, H2 2014 21 Assessment by Monotherapy Products, H2 2014 22 Number of Products by Stage and Target, H2 2014 24 Number of Products by Stage and Mechanism of Action, H2 2014 26 Number of Products by Stage and Route of Administration, H2 2014 28 Number of Products by Stage and Molecule Type, H2 2014 30 Hemorrhage - Dormant Projects, H2 2014 41
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.